A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS

Denise C. Hsu, Kimberly F. Faldetta, Luxin Pei, Virginia Sheikh, Netanya S. Utay, Gregg Roby, Adam Rupert, Anthony S. Fauci, Irini Sereti

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

Original languageEnglish (US)
Pages (from-to)258-261
Number of pages4
JournalClinical Infectious Diseases
Volume62
Issue number2
DOIs
StatePublished - Jan 15 2016

Keywords

  • immune reconstitution inflammatory syndrome
  • infliximab
  • mycobacterial infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS'. Together they form a unique fingerprint.

  • Cite this

    Hsu, D. C., Faldetta, K. F., Pei, L., Sheikh, V., Utay, N. S., Roby, G., Rupert, A., Fauci, A. S., & Sereti, I. (2016). A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. Clinical Infectious Diseases, 62(2), 258-261. https://doi.org/10.1093/cid/civ841